Long-Term Remissions of Severe Pemphigus After Rituximab Therapy Are Associated with Prolonged Failure of Desmoglein B Cell Response
Published 2013 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Long-Term Remissions of Severe Pemphigus After Rituximab Therapy Are Associated with Prolonged Failure of Desmoglein B Cell Response
Authors
Keywords
-
Journal
Science Translational Medicine
Volume 5, Issue 175, Pages 175ra30-175ra30
Publisher
American Association for the Advancement of Science (AAAS)
Online
2013-03-07
DOI
10.1126/scitranslmed.3005166
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Effect of a Single-Cycle Alternative Dosing Regimen for Rituximab for Recalcitrant Pemphigus
- (2012) Setsuko Matsukura et al. ARCHIVES OF DERMATOLOGY
- Therapy with rituximab for autoimmune pemphigus: Results from a single-center observational study on 42 cases with long-term follow-up
- (2012) Giuseppe Cianchini et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Immunosuppressive therapy for autoimmune bullous diseases
- (2011) Michael Meurer CLINICS IN DERMATOLOGY
- Current therapy of the pemphigus group
- (2011) Michael Kasperkiewicz et al. CLINICS IN DERMATOLOGY
- Rituximab used as a first-line single agent in the treatment of pemphigus vulgaris
- (2011) Emma E. Craythorne et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Recommendations for the use of rituximab in anti-neutrophil cytoplasm antibody-associated vasculitis
- (2011) M.-J. C. J. Guerry et al. RHEUMATOLOGY
- A Plasmablast Biomarker for Nonresponse to Antibody Therapy to CD20 in Rheumatoid Arthritis
- (2011) K. Owczarczyk et al. Science Translational Medicine
- Am"B"valent: anti-CD20 antibodies unravel the dual role of B cells in immunopathogenesis
- (2010) O. Thaunat et al. BLOOD
- Rituximab as Maintenance Therapy for Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
- (2010) E. P. Rhee et al. Clinical Journal of the American Society of Nephrology
- Rituximab Therapy in Lupus Nephritis: Current Clinical Evidence
- (2010) Manuel Ramos-Casals et al. CLINICAL REVIEWS IN ALLERGY & IMMUNOLOGY
- CD19+CD24hiCD38hi B Cells Exhibit Regulatory Capacity in Healthy Individuals but Are Functionally Impaired in Systemic Lupus Erythematosus Patients
- (2010) Paul A. Blair et al. IMMUNITY
- The efficacy and safety of rituximab for the treatment of active rheumatoid arthritis: a systematic review and meta-analysis of randomized controlled trials
- (2010) Young Ho Lee et al. RHEUMATOLOGY INTERNATIONAL
- A multicenter survey of rituximab therapy for refractory antineutrophil cytoplasmic antibody-associated vasculitis
- (2009) Rachel B. Jones et al. ARTHRITIS AND RHEUMATISM
- Current status on B-cell depletion therapy in autoimmune diseases other than rheumatoid arthritis
- (2009) Thomas Dörner et al. AUTOIMMUNITY REVIEWS
- Regulatory B cells as inhibitors of immune responses and inflammation
- (2008) Jean-David Bouaziz et al. IMMUNOLOGICAL REVIEWS
- Rituximab Exerts a Dual Effect in Pemphigus Vulgaris
- (2008) Rüdiger Eming et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- B-Cell Depletion Immunotherapy in Pemphigus: Effects on Cellular and Humoral Immune Responses
- (2008) Hugo Mouquet et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- Consensus statement on definitions of disease, end points, and therapeutic response for pemphigus
- (2008) Dedee F. Murrell et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- A dose-escalation study of rituximab for treatment of systemic lupus erythematosus and Evans' syndrome: immunological analysis of B cells, T cells and cytokines
- (2008) Y. Tamimoto et al. RHEUMATOLOGY
- Pathophysiological aspects of memory B-cell development
- (2007) Sandrine Roulland et al. TRENDS IN IMMUNOLOGY
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now